BLA 761333 · Amgen INC
Bkemv
Eculizumab-Aeeb · Injection · Complement Inhibitor
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
May 28, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
119
51 Phase 3, 11 recruiting
FAERS reports
11
8 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS MENINGOCOCCAL INFECTIONS Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1) ] . Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of BKEMV, unless the risks of delaying therapy with BKEMV outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional...
What it is approved for
From the label in effect Jul 2, 2026.
BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ( 1.3 ) The treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.4 ) 1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) BKEMV is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. 1.2 Atypical Hemolytic Uremic Syndrome (aHUS) BKEMV is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). 1.3 Generalized Myasthenia Gravis (gMG) BKEMV is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. 1.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) BKEMV is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Mechanism: Eculizumab-aeeb, the active ingredient in BKEMV, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. Eculizumab products inhibit terminal complement-mediated intravascular hemolysis in PNH patients and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS. The precise mechanism by which eculizumab products exert their therapeutic effect in gMG patients is unknown, but is presumed to involve reduction of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BKEMV · ECULIZUMAB-AEEB 300MG/30ML(10MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Eculizumab" as an intervention, any sponsor and status, largest first.
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDPivotal-lookingRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT07010302 · 540 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 2030
Drug: Rituximab (R); Eculizumab (Soliris®) and 3 more · For: NMOSD
Sites: Boston, Massachusetts; Berlin, Germany · 3 sites in all
- Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)Pivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT02145182 · 288 participants · Start Aug 21, 2014 · Primary completion Nov 22, 2016
Drug: Eculizumab; Placebo · For: Delayed Graft Function
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 78 sites in all
- ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)Pivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT02946463 · 272 participants · Start Dec 12, 2016 · Primary completion Feb 28, 2023
Drug: Ravulizumab; Eculizumab · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Los Angeles, California; Whittier, California; Fort Worth, Texas · 120 sites in all
- Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy SubjectsPivotal-lookingCompleted
Samsung Bioepis Co., Ltd.Industry
NCT03722329 · 240 participants · Start Nov 13, 2018 · Primary completion Mar 29, 2019
Drug: Eculizumab · For: Healthy
Sites: Berlin, Germany
- A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitorsPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04434092 · 210 participants · Start Oct 8, 2020 · Primary completion Nov 16, 2022
Drug: Crovalimab; Eculizumab · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Ciudad Autonoma Buenos Aires, Argentina; Santo André, Brazil; São Paulo, Brazil · 63 sites in all
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05744921 · 202 participants (planned) · Start Mar 7, 2023 · Primary completion Oct 10, 2028
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Curitiba, Brazil; São Paulo, Brazil; Toronto, Canada · 50 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05133531 · 202 participants · Start Aug 1, 2022 · Primary completion Sep 28, 2026
Drug: Ravulizumab; Pozelimab and 2 more · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Whittier, California; Santo André, Brazil; São Paulo, Brazil · 68 sites in all
- ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With EculizumabPivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT03056040 · 202 participants · Start May 17, 2017 · Primary completion Feb 21, 2022
Drug: Ravulizumab; Eculizumab · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Duarte, California; Los Angeles, California; Baltimore, Maryland · 51 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death2
- arthropathy1
- fatigue1
- gallbladder operation1
- gastrointestinal haemorrhage1
- hospitalisation1
- muscle discomfort1
- off label use1
- premature baby1
- product use in unapproved indication1
- rash1
- renal transplant1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P, Szer J, Weitz I, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF, Utsugisawa K, Benatar M, et al. · Lancet Neurol 2017 · Clinical Trial, Phase III, Multicenter Study
- Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ, Berthele A, Fujihara K, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD, Bannerman F, Beresford MW, et al. · BMC Nephrol 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. · Blood 2019 · Clinical Trial, Phase III, Comparative Study
- The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P, Young NS, Schubert J, et al. · N Engl J Med 2006 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.